Page 2477 - Williams Hematology ( PDFDrive )

2448 Index Index 2449

Hyperimmunoglobulin M syndromes, Hypodiploidy, 175t, 222t Chuvash polycythemia. See Chuvash
1213–1215 Hypodysfibrinogenemia. See polycythemia
autosomal recessive caused by intrinsic Dysfibrinogenemia/ classic von Hippel-Lindau syndrome,
B-cell defect, 1215 hypodysfibrinogenemia 877–878
autosomal recessive with CD40 mutations, Hypoferremia, 551 EPAS1 gain of function mutations, 878
1215 Hypofibrinogenemia. See Afibrinogenemia/ proline hydroxylase deficiency, 878
clinical and laboratory features, 1214t hypofibrinogenemia unexplained, 878
definition, 1213 Hypofibrinogenemic hemorrhage, 1397
genetic abnormalities, 1213 Hypogammaglobulinemia I
X-linked, with CD40L deficiency, 993, in chronic lymphocytic leukemia, 1531, IAP (inhibitor of apoptosis) proteins,
1213, 1575t 1541 207–208, 210, 1858–1859t
X-linked anhydrotic ectodermal dysplasia in myeloma, 1746 Iatrogenic lymphocytopenia, 1205–1206,
with immunodeficiency caused by Hypohalous acids, 284t 1205t
NEMO mutation, 1215 Hypokalemia I blood group, 2332t, 2334t, 2339, 2344t
Hyperkalemia in acute myelogenous leukemia, 1287, Ibrutinib, 342
in acute myelogenous leukemia, 1287 1383 adverse effects, 1203–1204, 1538
in chronic myelogenous leukemia, in chronic myelogenous leukemia, for chronic lymphocytic leukemia, 1538,
1448–1449 1448–1449 1540
Hyperleukocytic syndromes, 1285–1286 Hyponatremia, in acute myelogenous for mantle cell lymphoma, 1658–1659,
in acute lymphoblastic leukemia, 1514 leukemia, 1287, 1383 1660t
in acute myelogenous leukemia, 1285, Hypopituitarism, anemia and, 560–561 mechanism of action, 1529, 1538
1384 Hypoplastic anemia, 637 for Waldenström macroglobulinemia,
in chronic lymphocytic leukemia, 1540 Hypoplastic leukemia, 1384 1795
in chronic myelogenous leukemia, 1285, Hyposplenism, 867–869, 868t, 869f. Ibuprofen, 404, 2075
1449 See also Splenectomy ICAM, 932, 1007, 1008, 1184, 1185f
clinical features, 1286t Hypothermia, 2014 ICAM-1 (CD54)
complications, 1285–1286, 1396–1397 Hypothyroidism in eosinophils, 948, 950
laboratory features, 1285 acanthocytosis and, 680 in hemostasis, 1978
pathogenesis, 1092 anemia of, 559, 637 in inflammatory response, 282–283
treatment, 1286, 1397, 1514 Hypotonic lysis, 809 in lymphocytes, 1184
Hyperparathyroidism, anemia and, 561 Hypoxanthine-guanine phosphoribosyl in malaria, 815
Hyperplastic granulopoiesis, 983 transferase, 701t in myeloma, 1712
Hypersensitivity reactions, 1204, 2375 Hypoxanthine phosphoribosyltransferase in neutrophils, 1008
Hypersplenism, 863–867. See also (HPRT), 1439 ICAM-2 (CD102)
Splenomegaly Hypoxia in eosinophils, 950, 1008
clinical features, 864–865 chemically induced, 876 in hemostasis, 1978
definition, 863 high-altitude. See High-altitude in lymphocytes, 1184
imaging, 866f, 867f polycythemia in platelets, 1856, 1858t, 1859t, 1870
laboratory features, 866 macrophage phenotype and, 1071f ICAM-4, 462
pathophysiology, 864, 865t physiologic processes regulated by, 504, iCasp9 (inducible caspase-0 protein), 440,
therapy, course, and prognosis, 866–867 504f 440f
thrombocytopenia and, 2013 in pulmonary disease, 875 Iccosomes, 93
Hypertension, maternal, neonatal Hypoxia-inducible transcription factor ICE regimen
neutropenia and, 994 (HIF)-1, 486–487, 486f, 1071f for hepatosplenic T-cell lymphoma, 1701
Hyperthyroidism, anemia and, 559 Hypoxia-inducible transcription factor for Hodgkin lymphoma, 1616
Hyperuricemia, 1286, 1448, 1450 (HIF)-1α, 192, 196, 486–487, 503, for peripheral T-cell lymphoma, 1696
Hyperviscosity syndrome, 1746, 1788–1789, 877 iCOS (CD278), 1184
1789f, 1789t, 1792 Hypoxia-inducible transcription factor Icterus, neonatal, 689, 707, 709
Hypervolemia, 506, 510f (HIF)-2, 486–487, 486f, 503–504, ID3, 1672
Hypobetalipoproteinemia, acanthocytosis, 877, 1071f Idarubicin, 327–328
retinitis pigmentosa and pallidal Hypoxia-inducible transcription factor for acute myelogenous leukemia,
degeneration (HARP) syndrome, (HIF)-2α, 486–487, 486f, 510, 878 1395–1396, 1395t, 1402t
682 Hypoxia-inducible transcription factor for acute promyelocytic leukemia, 1404,
Hypochondriac, 863 (HIF)-2α mutations, 878 1405t
Hypochromia, 21f Hypoxia-response element (HRE), 484, 486 adverse effects, 328, 1519t
Hypodense eosinophils, 950 Hypoxia sensing, disorders of, 510, 876–878 for myelodysplastic syndromes, 1361

Kaushansky_index_p2393-2506.indd 2448 9/21/15 3:22 PM